Mianserin

Mianserin

SCHEMBL23326358

CN1CCN2c3ccccc3Cc3ccccc3C2C1.CN1CCN2c3ccccc3Cc3ccccc3C2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 8/20 1.00
HTR2A P28223 7/20 1.00
DRD2 P14416 7/20 1.00
HTR1A P08908 6/20 1.00
HTR2C P28335 5/20 1.00
HTR2B P41595 5/20 1.00
DRD4 P21917 4/20 1.00
HTR1D P28221 3/20 1.00
ADRA2A P08913 3/20 1.00
DRD1 P21728 3/20 1.00
ADRA1A P35348 3/20 1.00
LMNA P02545 2/20 1.00
MEN1 O00255 2/20 1.00
TP53 P04637 2/20 1.00
CYP3A4 P08684 2/20 1.00
KMT2A Q03164 2/20 1.00
CYP1A2 P05177 2/20 1.00
CYP2D6 P10635 2/20 1.00
CYP2C9 P11712 2/20 1.00
TSHR P16473 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mianserin SCHEMBL9122085 1.00 DRD3 (1.00) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL29356897 1.00 DRD3 (1.00) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL18020 1.00 DRD3 (1.00) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL353397 1.00 DRD3 (1.00) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL9752060 0.98 DRD3 (0.97) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL8344416 0.98 DRD3 (0.97) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL11336834 0.98 HTR2A (0.97) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL340474 0.98 MEN1 (1.00) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL29366576 0.98 MEN1 (1.00) DRD3HTR2ADRD2HTR1AHTR2C
Mianserin SCHEMBL2571368 0.97 DRD3 (0.94) DRD3HTR2ADRD2HTR1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210137853-A1 METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE ZOGENIX INTERNATIONAL LIMITED (GB) 2021-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210137853-A1 METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE SLC6A4, SLC1A2, SLC6A2 DRD3 522/4885HTR2A 6/4885DRD2 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.